About Allarity Therapeutics, Inc.
https://www.allarity.comAllarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology.
CEO
Thomas H. Jensen
Compensation Summary
(Year 2024)
Salary $507,850
Bonus $100,000
Incentive Plan Pay $183,750
Total Compensation $791,600
Industry Biotechnology
Sector Healthcare
Went public December 21, 2021
Method of going public Reverse Merger
Full time employees 6
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-09-11 | Reverse | 1:30 |
| 2024-04-09 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Total 1
Showing Top 1 of 1
Ratings Snapshot
Rating : C+
Discounted Cash Flow 3
Return On Equity 1
Return On Assets 1
Debt To Equity 3
Price To Earnings 1
Price To Book 3
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Buy 1
Showing Top 1 of 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
Summary
% Of Shares Owned 0.00%
Total Number Of Holders 1
Showing Top 1 of 1
Market Cap $18.82 M
52w High $2.35
52w Low $0.61
P/E 0.13
Volume 119.56K
Outstanding Shares 15.82M
About Allarity Therapeutics, Inc.
https://www.allarity.comAllarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $2.52M ▼ | $-2.81M ▼ | 0% | $-0.19 ▼ | $-2.75M ▼ |
| Q2-2025 | $0 | $4.13M ▲ | $-2.32M ▲ | 0% | $-0.15 ▲ | $-2.3M ▲ |
| Q1-2025 | $0 | $3.04M ▼ | $-2.73M ▲ | 0% | $-0.25 ▲ | $-2.66M ▲ |
| Q4-2024 | $0 | $7.32M ▼ | $-7.45M ▲ | 0% | $-1.02 ▲ | $-7.38M ▲ |
| Q3-2024 | $0 | $12.31M | $-11.59M | 0% | $-7.71 | $-11.91M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $16.89M ▼ | $20.8M ▼ | $8.79M ▼ | $12.01M ▼ |
| Q2-2025 | $17.8M ▼ | $21.2M ▼ | $9.04M ▼ | $12.17M ▼ |
| Q1-2025 | $25.2M ▲ | $29.73M ▲ | $11.06M ▲ | $18.67M ▲ |
| Q4-2024 | $19.53M ▲ | $22.65M ▲ | $10.84M ▲ | $11.81M ▼ |
| Q3-2024 | $18.46M | $20.38M | $7.41M | $12.96M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-2.81M ▼ | $-3.41M ▲ | $0 | $2.31M ▲ | $-906K ▲ | $-3.41M ▲ |
| Q2-2025 | $-2.32M ▲ | $-5.48M ▼ | $0 | $-2.56M ▼ | $-9.9M ▼ | $-5.48M ▼ |
| Q1-2025 | $-2.73M ▲ | $-2.69M ▲ | $0 ▲ | $11.14M ▲ | $8.17M ▲ | $-2.69M ▲ |
| Q4-2024 | $-7.45M ▲ | $-3.21M ▲ | $-298K ▼ | $4.24M ▼ | $1.07M ▲ | $-3.5M ▲ |
| Q3-2024 | $-11.59M | $-5.44M | $0 | $4.87M | $-770K | $-5.44M |
CEO
Thomas H. Jensen
Compensation Summary
(Year 2024)
Salary $507,850
Bonus $100,000
Incentive Plan Pay $183,750
Total Compensation $791,600
Industry Biotechnology
Sector Healthcare
Went public December 21, 2021
Method of going public Reverse Merger
Full time employees 6
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-09-11 | Reverse | 1:30 |
| 2024-04-09 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Total 1
Showing Top 1 of 1
Ratings Snapshot
Rating : C+
Discounted Cash Flow 3
Return On Equity 1
Return On Assets 1
Debt To Equity 3
Price To Earnings 1
Price To Book 3
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Buy 1
Showing Top 1 of 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
Summary
% Of Shares Owned 0.00%
Total Number Of Holders 1
Showing Top 1 of 1